Literature DB >> 27415034

Perspectives on investigational drugs and immunotherapies for glioblastoma.

Julie J Miller1,2, William T Curry1,3, Dan P Cahill1,3, Jörg Dietrich1,2.   

Abstract

Entities:  

Keywords:  Glioblastoma; IDH; immune checkpoint inhibition; immunotherapy; vaccination

Mesh：

Substances：

Year:  2016        PMID： 27415034      PMCID： PMC5018991          DOI： 10.1080/13543784.2016.1213242

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.498


× No keyword cloud information.
  20 in total

1.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Authors:  Meghan J Seltzer; Bryson D Bennett; Avadhut D Joshi; Ping Gao; Ajit G Thomas; Dana V Ferraris; Takashi Tsukamoto; Camilo J Rojas; Barbara S Slusher; Joshua D Rabinowitz; Chi V Dang; Gregory J Riggins
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 2.  Immunomodulation: checkpoint blockade etc.

Authors:  William T Curry; Michael Lim
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

3.  Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.

Authors:  William T Curry; Ramana Gorrepati; Matthias Piesche; Tetsuro Sasada; Pankaj Agarwalla; Pamela S Jones; Elizabeth R Gerstner; Alexandra J Golby; Tracy T Batchelor; Patrick Y Wen; Martin C Mihm; Glenn Dranoff
Journal:  Clin Cancer Res       Date:  2016-02-12       Impact factor: 12.531

4.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

5.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

6.  A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.

Authors:  Adnan Elhammali; Joseph E Ippolito; Lynne Collins; Jan Crowley; Jayne Marasa; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-04-16       Impact factor: 39.397

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Authors:  Alexandra Borodovsky; Vafi Salmasi; Sevin Turcan; Armida W M Fabius; Gilson S Baia; Charles G Eberhart; Jon D Weingart; Gary L Gallia; Stephen B Baylin; Timothy A Chan; Gregory J Riggins
Journal:  Oncotarget       Date:  2013-10

9.  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.

Authors:  Surasak Phuphanich; Christopher J Wheeler; Jeremy D Rudnick; Mia Mazer; Hongqian Wang; Miriam A Nuño; Jaime E Richardson; Xuemo Fan; Jianfei Ji; Ray M Chu; James G Bender; Elma S Hawkins; Chirag G Patil; Keith L Black; John S Yu
Journal:  Cancer Immunol Immunother       Date:  2012-07-31       Impact factor: 6.968

10.  Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Authors:  Duane A Mitchell; Kristen A Batich; Michael D Gunn; Min-Nung Huang; Luis Sanchez-Perez; Smita K Nair; Kendra L Congdon; Elizabeth A Reap; Gary E Archer; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; April Coan; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; John H Sampson
Journal:  Nature       Date:  2015-03-11       Impact factor: 49.962
View more
  1 in total

1.  Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.

Authors:  Nusrat Jahan; Hammad Talat; Andrea Alonso; Dipongkor Saha; William T Curry
Journal:  Oncoimmunology       Date:  2019-02-27       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.